Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026

ConferenceAglatimagene BesadenovecPositive

AI Analysis

Summary

Candel Therapeutics announced acceptance of an abstract for poster presentation of extended Phase 3 data on aglatimagene besadenovec at the 2026 ASTRO Annual Meeting in September 2026.

Clinical Trial Data

Phase

Phase 3

Importance:3/10

Sentiment:

0.30

Phase 3cancer immunotherapyconference presentationASTRO 2026

Related Companies

$CADL

Read the original article

Published by GlobeNewswire Clinical Studies on August 3, 2026 12:05 PM

Read Original